INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Apogee Enterprises, Inc. - APOG

09.01.26 04:16 Uhr

Werte in diesem Artikel
Aktien

30,20 EUR 1,60 EUR 5,59%

NEW YORK, Jan. 8, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Apogee Enterprises, Inc. ("Apogee" or the "Company") (NASDAQ: APOG). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

Fighting for victims of securities fraud for more than 85 years (PRNewsfoto/Pomerantz LLP)

The investigation concerns whether Apogee and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On January 7, 2026, Apogee reported its financial results for the third quarter of its 2026 fiscal year. Among other items, Apogee reported $355.3 million in sales, missing the consensus estimate of $348.6 million. Apogee's Chief Executive Officer said that "higher aluminum, restructuring and health insurance costs" all weighed on the Company's results. 

On this news, Apogee's stock price fell $5.18 per share, or 13.89%, to close at $32.11 per share on January 7, 2026.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes. 

CONTACT:
Danielle Peyton
Pomerantz LLP
dpeyton@pomlaw.com
646-581-9980 ext. 7980

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-apogee-enterprises-inc---apog-302656930.html

SOURCE Pomerantz LLP

In eigener Sache

Übrigens: Apogee Enterprises und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und Neukunden-Bonus sichern!

Ausgewählte Hebelprodukte auf Apogee Enterprises

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Apogee Enterprises

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Nachrichten zu Apogee Enterprises

Wer­bung

Analysen zu Apogee Enterprises

DatumRatingAnalyst
26.06.2015Apogee Enterprises Market PerformNorthland Capital
15.06.2015Apogee Enterprises BuyD.A. Davidson & Co.
10.04.2015Apogee Enterprises OutperformNorthland Capital
23.09.2014Apogee Enterprises OutperformNorthland Capital
18.09.2014Apogee Enterprises BuyD.A. Davidson & Co.
DatumRatingAnalyst
15.06.2015Apogee Enterprises BuyD.A. Davidson & Co.
10.04.2015Apogee Enterprises OutperformNorthland Capital
23.09.2014Apogee Enterprises OutperformNorthland Capital
18.09.2014Apogee Enterprises BuyD.A. Davidson & Co.
DatumRatingAnalyst
26.06.2015Apogee Enterprises Market PerformNorthland Capital
18.09.2012Apogee Enterprises neutralD.A. Davidson & Co.
DatumRatingAnalyst

Keine Analysen im Zeitraum eines Jahres in dieser Kategorie verfügbar.

Eventuell finden Sie Nachrichten die älter als ein Jahr sind im Archiv

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Apogee Enterprises nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen